Chang, David Z.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 1,222

Ras Activity Levels Control the Development of Pancreatic Diseases

Ji, B., Tsou, L., Wang, H., Gaiser, S., Chang, D. Z., Daniluk, J., Bi, Y., Grote, T., Longnecker, D. S., & Logsdon, C. D. (2009) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 194

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Fakih, M., Raghav, K. P. S., Chang, D. Z., Bendell, J. C., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Garbo, L. E., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 72